ATE64304T1 - Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen. - Google Patents

Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.

Info

Publication number
ATE64304T1
ATE64304T1 AT86302781T AT86302781T ATE64304T1 AT E64304 T1 ATE64304 T1 AT E64304T1 AT 86302781 T AT86302781 T AT 86302781T AT 86302781 T AT86302781 T AT 86302781T AT E64304 T1 ATE64304 T1 AT E64304T1
Authority
AT
Austria
Prior art keywords
specific antigen
antigen
immuntolerance
confering
methods
Prior art date
Application number
AT86302781T
Other languages
English (en)
Inventor
C Garrison Fathman
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE64304T1 publication Critical patent/ATE64304T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT86302781T 1985-04-17 1986-04-15 Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen. ATE64304T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/724,063 US4681760A (en) 1985-04-17 1985-04-17 Method of conferring immunotolerance to a specific antigen
EP86302781A EP0200412B1 (de) 1985-04-17 1986-04-15 Verfahren zur Verleihung von Immuntoleranz gegen ein spezifisches Antigen

Publications (1)

Publication Number Publication Date
ATE64304T1 true ATE64304T1 (de) 1991-06-15

Family

ID=24908815

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86302781T ATE64304T1 (de) 1985-04-17 1986-04-15 Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.

Country Status (6)

Country Link
US (1) US4681760A (de)
EP (1) EP0200412B1 (de)
JP (1) JP2530316B2 (de)
AT (1) ATE64304T1 (de)
CA (1) CA1266232A (de)
DE (1) DE3679708D1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
US4842862A (en) * 1986-07-03 1989-06-27 International Minerals & Chemical Corp. Immunostimulating agents
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
USRE38008E1 (en) 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5723128A (en) * 1987-01-30 1998-03-03 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides
US7011834B1 (en) 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US4898730A (en) * 1987-03-13 1990-02-06 The University Of British Columbia Method to stimulate the immune response to specific antigens
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
CA1336818C (en) * 1987-04-16 1995-08-29 International Institute Of Cellular And Molecular Pathology Treatment of allergy and composition thereof
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5422258A (en) * 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
EP0407399A4 (en) * 1988-02-03 1991-06-19 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions
CA1340494C (en) * 1988-05-19 1999-04-13 The Beth Israel Hospital Association And Brigham And Women's Hospital Induction of tolerance to a foreign antigen
US5152980A (en) * 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
DE68924850T2 (de) * 1988-06-14 1996-10-10 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
CA2015515C (en) 1990-01-03 1999-12-07 Jean-Marie Saint-Remy Pharmaceutical compositions containing antigen-antibody complexes and uses therefor
WO1992000100A1 (en) * 1990-06-22 1992-01-09 E.I. Du Pont De Nemours And Company Improved ascites production of monoclonal antibodies using an immunosuppressive anti-cd4-related antibody
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
WO1993009141A1 (en) 1991-11-01 1993-05-13 Joslin Diabetes Center Antigen associated with type i diabetes mellitus
WO1993016725A1 (en) * 1992-02-27 1993-09-02 The Board Of Trustees Of The Leland Stanford Junior University Early antigen for autoimmune diabetes
JPH08502244A (ja) * 1992-08-11 1996-03-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫調節ペプチド
EP0671926B1 (de) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunmodulierende peptide
US6696061B1 (en) 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
JPH08332344A (ja) * 1995-06-09 1996-12-17 Honda Motor Co Ltd 内燃機関の排気浄化装置
ATE255910T1 (de) * 1996-04-10 2003-12-15 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
EE200100123A (et) * 1998-08-31 2002-06-17 Biogen, Incorporated CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
CN1441676B (zh) * 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
WO2003009740A2 (en) * 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
EP2168598A1 (de) * 2001-09-28 2010-03-31 Purdue Research Foundation Verfahren zur Behandlung mit Ligand-Immunogen-Konjugaten
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
WO2005077018A2 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
MXPA06012744A (es) * 2004-05-04 2007-02-19 Genaissance Pharmaceutical Inc Marcadores de haplotipo y metodos para utilizarlos en la determinacion de la respuesta al tratamiento.
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
US8722343B2 (en) 2008-11-21 2014-05-13 Carla Perego Methods and compositions for the diagnosis and treatment of diabetes
EP3936137A1 (de) 2013-02-07 2022-01-12 The General Hospital Corporation Verfahren zur expansion oder abreicherung von t-regulatorischen zellen
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3355914B1 (de) 2015-09-29 2024-03-06 The General Hospital Corporation Eine bcg-haltige zusammensetzung zur cholesterolsenkung.
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
WO1979000160A1 (en) * 1977-09-28 1979-04-05 Nat Res Dev Improvements in or relating to immunological preparations
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
ATE60233T1 (de) * 1983-09-15 1991-02-15 Univ Leland Stanford Junior Allotransplantat mit verminderter immunogenitaet und verfahren und reagenz fuer seine herstellung.
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells

Also Published As

Publication number Publication date
DE3679708D1 (de) 1991-07-18
US4681760A (en) 1987-07-21
CA1266232A (en) 1990-02-27
EP0200412A3 (en) 1988-03-30
EP0200412A2 (de) 1986-11-05
EP0200412B1 (de) 1991-06-12
JP2530316B2 (ja) 1996-09-04
JPS6236A (ja) 1987-01-06

Similar Documents

Publication Publication Date Title
ATE64304T1 (de) Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.
DE3882686D1 (de) Vorbereitungssystem von knotenserien des wegendes in einem navigationsgeraet.
FI902143A7 (fi) HIV-peptidit, keinotekoiset HIV-antigeenit ja immunomäärityspakkaukset
DK0504177T3 (da) IL-11, et pattedyrcytokin
DE3854644D1 (de) Verfahren und Vorrichtungen zur Zellenbestimmung.
DE3875667D1 (de) Menschliche papillomavirusnukleinsaeureproben.
PT86640A (pt) Hepatitis b virus surface antigens and hybrid antigens containing them
FI882746A7 (fi) Hybridiproteiini C ja menetelmä sen valmistamiseksi.
DE3679526D1 (de) Verfahren und vorrichtung fuer das ausrichten von einzelblaettern.
JPS54126596A (en) Method of detecting or fixing virus antigen or red blood* bacteria antigen or antigen
DE3874387D1 (de) Immunologische methoden und materialien zur bestimmung von tumor assoziierten antigenen.
AU5768986A (en) Filamentous haemagglutinin and pertussis antigen vaccines from bordetella
FI811685A7 (fi) Menetelmä virusperäisten glykoproteiiniantigeenien eristämiseksi ja niiden käyttö rokotteiden vvalmistukseen.
FI874676L (fi) Menetelmä anti-HIV:n määrittämiseksi, tarvikkeet sitä varten ja niiden käyttö tässä menetelmässä
FI882131L (fi) Vinyylikopolymeeri ja menetelmä sen valmistamiseksi
IE881282L (en) Monoclonal antibodies to specific antigenic regions of the¹human immunodeficiency virus and methods for use.
FI885868A7 (fi) Menetelmä immuunikatoviruksen vasta-aineiden havaitsemiseksi
KR880700853A (ko) Aids를 유발시킬수 있는 신규 레트로비루스와 실험관내에서 그것을 검출하기 위한 수단 및 방법
DE3888887D1 (de) Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
FI881355A7 (fi) Määritysmenetelmä hepatiittiantigeenien ja AIDS-vasta-aineiden toteamiseksi.
DE3681805D1 (de) Vorrichtung fuer zellkulturen und verfahren.
DE3674104D1 (de) Verfahren zur ausbildung von cuinse2-filmen.
FI884225A7 (fi) Uusia aminohappoestereitä, menetelmiä niiden valmistamiseksi, niitä sisältäviä lääkeaineita ja niiden käyttö.
DE3672327D1 (de) Verfahren und vorrichtung zur automatischen stapelung von elementen.
ATE108664T1 (de) Verfahren zur verhütung von gvhd.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee